A Phase 2, Randomized, Open-label Study of VVD-133214 with Pembrolizumab versus Pembrolizumab Monotherapy in Advanced MSI-H/dMMR Colorectal Adenocarcinoma
Sponsor: Vividion Therapeutics Inc.
Phase: 2
Disease: Advanced colorectal adenocarcinoma, Metastatic colorectal cancer
EU trial number: 2026-525507-26-00
Population: Adults aged 18 years or older (19 in Japan and South Korea) with unresectable or metastatic colorectal adenocarcinoma, MSI-high and/or deficient mismatch repair confirmed locally, ECOG 0-1, measurable RECIST v1.1 disease, and no prior systemic therapy for metastatic disease.
Register Investigator Interest
Interested in offering this trial to suitable patients?